Health Care & Life Sciences » Pharmaceuticals | Acura Pharmaceuticals Inc.

Acura Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
123.00
751.00
8,587.00
4,464.00
2,966.00
Cost of Goods Sold (COGS) incl. D&A
248.00
274.00
656.00
451.00
422.00
Gross Income
125.00
477.00
7,931.00
4,013.00
2,544.00
SG&A Expense
13,715.00
12,475.00
11,602.00
10,544.00
7,769.00
EBIT
14,090.00
12,199.00
4,001.00
6,557.00
5,225.00
Non Operating Income/Expense
4.00
4.00
3.00
2.00
-
Interest Expense
9.00
1,212.00
1,157.00
893.00
596.00
Pretax Income
13,901.00
13,209.00
4,989.00
7,388.00
5,817.00
Income Tax
-
-
-
-
135.00
Consolidated Net Income
13,901.00
13,209.00
4,989.00
7,388.00
5,682.00
Net Income
13,901.00
13,209.00
4,989.00
7,388.00
5,682.00
Net Income After Extraordinaries
13,901.00
13,209.00
4,989.00
7,388.00
5,682.00
Net Income Available to Common
13,901.00
13,209.00
4,989.00
7,388.00
5,682.00
EPS (Basic)
1.45
1.35
0.46
0.62
0.36
Basic Shares Outstanding
9,552.80
9,778.60
10,796.00
11,870.00
15,903.00
EPS (Diluted)
1.46
1.35
0.46
0.62
0.36
Diluted Shares Outstanding
9,552.80
9,778.60
10,796.00
11,870.00
15,903.00
EBITDA
13,956.00
11,925.00
3,669.00
6,212.00
4,931.00
Other Operating Expense
250.00
201.00
330.00
26.00
-
Non-Operating Interest Income
194.00
198.00
166.00
60.00
4.00

About Acura Pharmaceuticals

View Profile
Address
616 N. North Court
Palatine Illinois 60067
United States
Employees -
Website http://www.acurapharm.com
Updated 07/08/2019
Acura Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary aversion and impede technologies. It operates its business through the research, development, and manufacture of innovative abuse deterrent, orally administered pharmaceutical products. The company was founded in 1935 and is headquartered in Palatine, IL.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.